Current Report Filing (8-k)
March 16 2017 - 9:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): March 16, 2017
OPIANT PHARMACEUTICALS, INC.
(
Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55330
|
|
46-4744124
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission File Number
|
|
(IRS Employer Identification No.)
|
401 Wilshire Blvd., 12th Floor
Santa Monica, CA
|
|
90401
|
(Address of Principal Executive
Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code
|
(Former name or former address if changed since last report,)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item
2.02
|
Results
of Operations and Financial Condition.
|
On March 16, 2017, Opiant Pharmaceuticals, Inc., a Nevada corporation (the “Company”), issued a press release announcing
(i) the Company’s financial results for the second quarter ended January 31, 2017, (ii) recent highlights which occurred
during and after the second quarter ended January 31, 2017, and (iii) certain upcoming 2017 corporate and clinical goals. A copy
of the press release is furnished herewith as Exhibit 99.1.*
* The information in Item 2.02 of this Form 8-K shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Opiant Pharmaceuticals, Inc. Press Release, dated March 16, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Opiant Pharmaceuticals, Inc.
|
|
|
|
Date: March 16, 2017
|
By:
|
/s/
Dr. Roger Crystal
|
|
|
Name: Dr. Roger Crystal
|
|
|
Title: Chief Executive Officer
|
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
From Apr 2023 to Apr 2024